 SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 GLOBE NEWSWIRE -- Catalyst Biosciences, Inc. NASDAQ: CBIO today presented positive pre-clinical data from its Marzeptacog alfa activated MarzAA, program, the Companys subcutaneously SQ administered next-generation engineered activated coagulation Factor VII FVIIa for the treatment of episodic bleeding that is entering a Phase 3 registration trial. The data were presented by Tom Knudsen, D.V.M., Ph.D., vice president of translational research and Howard Levy, M.B.B.Ch., Ph.D., M.M.M., chief medical officer in poster sessions at the virtual 14th Annual Congress of the European Association for Haemophilia and Allied Disorders EAHAD. 